2017-03-09,Dimension Therapeutics Announces Full Year 2016 Financial Results And Recent Updates Across Rare And Metabolic Disease Portfolio And In HeLa Manufacturing
2017-03-07,Dimension Therapeutics To Hold Full Year 2016 Financial Results And Recent Program Updates Conference Call
2017-02-17,Lifshitz & Miller LLP Announces Investigation Of BT Group Plc, Celadon Group, Inc., Community Health Systems, Inc., Dimension Therapeutics, Inc., Home Capital Group Inc., Lifevantage Corporation, OvaScience, Inc. And Under Armour, Inc.
2017-02-14,Newman Ferrara LLP Announces Corporate Governance Investigation Of Dimension Therapeutics Inc.
2017-02-07,Dimension Therapeutics Elects Dr. John A. Hohneker To Its Board Of Directors
2017-02-02,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Dimension Therapeutics, Inc.
2017-01-31,Dimension Announces Interim Topline Results From Ongoing Phase 1/2 Clinical Program For DTX101, Dimension's Lead AAV Product Candidate In Development For Adult Patients With Moderate/Severe To Severe Hemophilia B
2016-12-13,Dimension Therapeutics Announces FDA Acceptance Of Investigational New Drug Application For DTX301 To Treat OTC Deficiency
2016-12-05,Dimension Therapeutics Announces Presentation At The 58th American Society Of Hematology (ASH) Annual Meeting
2016-11-29,Dimension Therapeutics Receives Positive Opinion For European Orphan Drug Designation Of DTX401 For The Treatment Of Glycogen Storage Disease Type Ia (GSDIa)
2016-11-23,Ratings Changes Today
2016-11-10,Dimension Therapeutics Reports Recent Corporate Progress And Third Quarter 2016 Financial Results
2016-11-03,Dimension Therapeutics Announces Presentation At The Upcoming 58th American Society Of Hematology (ASH) Annual Meeting
2016-10-18,Dimension Therapeutics Announces Presentations Highlighting Advances In AAV Manufacturing At The European Society Of Gene And Cell Therapy (ESGCT) Congress
2016-10-11,Dimension Therapeutics Announces Presentations At The Upcoming European Society Of Gene And Cell Therapy (ESGCT) Congress
2016-10-04,Dimension Therapeutics Announces Orphan Drug Designation Of DTX401 For The Treatment Of Glycogen Storage Disease Type Ia (GSDIa)
2016-08-24,Dimension Therapeutics Announces Participation In Two Upcoming Investor Conferences
2016-08-11,Dimension Therapeutics Reports Recent Corporate Progress And Second Quarter 2016 Financial Results
2016-08-02,Dimension Therapeutics To Present At The Canaccord Genuity 36th Annual Growth Conference
2016-07-08,These 5 Stocks Are Breaking Out
2016-07-07,Aptuit LLC And Dimension Therapeutics Enter Strategic Partnership To Advance Select Dimension Programs Toward IND Filing
2016-06-29,Dimension Therapeutics To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
2016-06-27,Dimension Therapeutics Becomes Oversold (DMTX)
2016-06-22,Dimension Therapeutics Announces Recombinant DNA Advisory Committee's Unanimous Approval Of Phase 1/2 Study Protocol For DTX301, Lead Inherited Metabolic Disease (IMD) Product Candidate To Treat OTC Deficiency
2016-06-21,Dimension Therapeutics Opens New Facility In Woburn And Expands Management Team
2016-05-31,Dimension Therapeutics To Present At Two Upcoming Investor Conferences
2016-05-27,Dimension Therapeutics Announces Presentations At The 8th European Conference On Rare Diseases & Orphan Products (ECRD)
2016-05-20,7 Stocks Under $10 Making Big Moves Higher
2016-05-19,Dimension Therapeutics Announces Presentations At The Upcoming 21st Congress Of The European Hematology Association (EHA)
2016-05-12,Dimension Therapeutics Reports Recent Corporate Progress And First Quarter 2016 Financial Results
2016-05-07,Dimension Therapeutics Announces Preclinical Data From Bayer-Partnered Hemophilia A Program At American Society For Gene And Cell Therapy (ASGCT) Annual Meeting
2016-05-05,Dimension Therapeutics Announces Gene Therapy Research Collaboration With The University Of Pennsylvania And Expansion Of Inherited Metabolic Disease Portfolio
2016-05-05,Dimension Therapeutics Announces Preclinical Data Supporting Ongoing DTX101 Phase 1/2 Clinical Trial At American Society For Gene And Cell Therapy (ASGCT) Annual Meeting
2016-04-28,Dimension Therapeutics Announces Participation In Two Upcoming Conferences
2016-04-18,Dimension Therapeutics Announces Presentations At The Upcoming American Society For Gene And Cell Therapy (ASGCT) Annual Meeting
2016-04-06,Dimension Therapeutics To Present At The British Society For Gene And Cell Therapy (BSGCT) Annual Conference
2016-03-24,Dimension Therapeutics Reports Recent Corporate Progress And Full Year 2015 Financial Results
2016-03-17,Dimension Therapeutics Receives Positive Opinion For European Orphan Drug Designation For DTX301 For The Treatment Of Ornithine Transcarbamylase (OTC) Deficiency
2016-03-01,Dimension Therapeutics To Present At Two Upcoming Investor Conferences
2016-01-27,Dimension Therapeutics To Participate In Canaccord Genuity 2016 Rare Disease Biopharma Day And SunTrust Robinson Humphrey 2016 Orphan Drug Day
2016-01-07,Dimension Therapeutics Announces Initiation Of Phase 1/2 Study For DTX101 For The Treatment Of Hemophilia B
2016-01-06,Dimension Therapeutics Announces Orphan Drug Designation Of DTX301 For The Treatment Of Ornithine Transcarbamylase (OTC) Deficiency
2015-12-04,Dimension Therapeutics Reports Recent Corporate Progress And Third Quarter 2015 Financial Results
2015-11-03,Dimension Therapeutics Announces Expansion Of Internal Research And Process Development Capabilities
,
,
,
,
